Insulet Corp

XMUN:GOV

Business Description

Sector

Health Care

Industry

Health Care

Headquarters

United States of America US

Employees

5 400

IPO date

May 15, 2007

Insulet makes wearable insulin delivery systems for people with diabetes. Its main product is the Omnipod line, a small tubeless pump that sticks to the body and automatically delivers insulin without the need for repeated injections. The company also provides the disposable pods, the controller or app that manages dosing, and training and support for patients and healthcare providers.

Its main customers are people with type 1 diabetes and some people with type 2 diabetes who need insulin therapy, along with hospitals, clinics, and prescribing doctors who help choose the device. Insulet earns money mostly by selling the pods that must be replaced regularly, along with the starter systems and related supplies that go with them. That creates a recurring revenue model tied to continued patient use rather than one-time equipment sales.

What makes Insulet different is that it is not a broad medical device company; it is focused on a single category of diabetes care: tubeless automated insulin delivery. In the insulin pump market, it sits between drug makers that supply insulin and the healthcare providers who prescribe diabetes technology, giving it a specialized role in a treatment workflow that patients use every day.